June 25, 2020
IntegriChain appoints Dharma Subramanian, a seasoned product leader, as Vice President, Data Products and ICyte Analytics. Subramanian delivers more than 15 years of product management and leadership including roles at Reltio, Veeva Systems, IBM, and Unisys. At IntegriChain, he will be responsible for the company’s channel and patient data and analytics products as well as the unified ICyte access data and business process platform.
June 24, 2020
IntegriChain and the Chamber of Commerce for Greater Philadelphia’s regional CEO Council for Growth’s Cell & Gene Therapy and Connected Health Initiative will offer a complimentary educational series for emerging cell and gene therapy companies. Focused on launch and commercial readiness, the three-part webinar series begins on Thursday, June 25.
May 18, 2020
IntegriChain is prominently featured in Gartner’s new Market Guide for Revenue Management in Pharmaceuticals and Biotechnology, which is available here from the Gartner.com website. Following IntegriChain’s acquisition of the Life Sciences Division of Cumberland last month, the report highlights the combined company’s flexible and agile revenue management data, analytics, and managed services platform.
April 21, 2020
IntegriChain has appointed a highly seasoned human resources executive as Senior Vice President of People and Culture. Vickie Kozhushchenko delivers more than 20 years of global HR experience, including senior executive roles at Clean Earth, Aramark, Turner Broadcasting System, Comcast and Coordinated Health and extensive acquisition integration experience. She is responsible for IntegriChain’s global HR organization, including the organization’s team development, recruiting and retention programs and policy.
April 13, 2020
IntegriChain has acquired Cumberland’s Life Science Division, a leading provider of managed services, advisory services and systems integration for contracts, pricing and revenue management. With this acquisition, IntegriChain delivers the Life Science industry’s most comprehensive and scalable data and business process platform for commercialization and market access of cell and gene therapy, specialty, and retail pharmaceuticals.
January 8, 2020
IntegriChain today announced that the company has supported more than 65 launches of innovative therapies including cell and gene therapy (CGT) and orphan & rare diseases (ORD) during the last three years. Emerging Life Sciences manufacturers have engaged IntegriChain for its best-in-class comprehensive commercialization platform, including channel and patient data stewardship and managed services to stand up their business infrastructure for all aspects of patient access: contracts and pricing, gross-to-net, channel, and patient services.
December 3, 2019
IntegriChain announced that multiple top-30 Life Sciences manufacturers have implemented its stewardship and refining solutions to improve the quality and actionability of specialty pharmacy data. These solutions, based on recent data science advancements in the ICyte Platform, overcome the industry challenge of immature patient data sets that includes non-standardize data from hundreds of data suppliers delivered with varied quality. IntegriChain Co-Founder and EVP Josh Halpern will present more on this topic during his presentation, “The State of Patient Status Visibility and the Use of Artificial Intelligence to Drive Specialty Channel Insights,” at CBI Trade & Channel, beginning today in Philadelphia.
November 12, 2019
IntegriChain completes implementation of its Gross-to-Net (GTN) Managed Services with Akcea Therapeutics. IntegriChain GTN Solutions, which are built to industry best practices and are scalable and auditable, deliver end-to-end revenue management for Life Sciences Market Access and Finance teams that improves forecast accuracy, GTN modeling, and financial close efficiency. IntegriChain also is finalizing the implementation-readiness process for five additional GTN Managed Services customers.
November 6, 2019
IntegriChain Co-Founder and CEO, Kevin Leininger, will speak at upcoming investor conferences. Leininger will present a company overview at AGC Partners’ 2019 Boston Technology Growth Conference on Thursday, November 7, and Lincoln International’s 2019 Growth Conference November 18 in Chicago.